PT-141: when low libido is a clinical issue worth treating

Low sexual desire that causes personal distress is a documented clinical entity. The DSM-5-TR classifies it under female sexual interest/arousal disorder, the diagnostic successor to what was previously called hypoactive sexual desire disorder, or HSDD [DSM-5-TR, American Psychiatric Association, 2022]. In the largest US population study, around 10% of women met the criteria for distressing low desire, with prevalence highest in women aged 45 to 64 [Shifren et al., Obstetrics & Gynecology, 2008]. The numbers in adult men are smaller but non-trivial.

This is not a fringe complaint and it is not a relationship-counselling problem in disguise. It is a quality-of-life issue with a clinical name, diagnostic criteria, and an expanding treatment toolkit. The job of this article is to write about it the way Mayo Clinic writes about female sexual dysfunction or male erectile dysfunction: clinically, respectfully, and with the evidence laid out plainly so a patient can decide what to do next.

One of those tools is bremelanotide, a synthetic peptide marketed as Vyleesi. The FDA approved it in 2019 for premenopausal women with HSDD [FDA prescribing information, Vyleesi]. It has phase III evidence, a defined mechanism, and a real side effect profile. It is also widely misunderstood, especially in regional markets where the conversation around sexual health has historically been quieter than the conversation around the underlying biology.

A note on talking about this in the UAE

Discussions of sexual health are culturally guarded in much of the region, and that's a fact a clinic should respect rather than lecture about. What it means in practice is that the family medicine visit in the UAE rarely includes a sexual-health screen, and patients rarely raise the topic unprompted. The result is a clinical literacy gap: a problem that's treatable goes unmentioned for years, sometimes decades.

The editorial position of this piece is straightforward. Treating low desire that causes a patient distress is the same kind of clinical work as treating insomnia, low energy, or any other quality-of-life complaint. It belongs in a doctor's office. The patient deserves a real workup, real evidence, and a real conversation about whether a medication is the right next step. That's the register we're writing in here.

Low desire is a symptom, not a diagnosis

The first job of a competent clinician is to resist treating low desire as if it were a single disease with a single drug. It is a symptom with a long differential, and skipping that differential is how patients end up on the wrong intervention.

The major causes a clinician should rule in or out before reaching for any medication include the following.

• Relationship factors. Low desire that tracks with a specific relationship, a specific period of conflict, or a specific change in the dynamic is unlikely to respond to any peptide. The International Society for the Study of Women's Sexual Health guidelines emphasize that relational context is part of the diagnostic picture and not a diagnosis of exclusion [ISSWSH, 2020].
• Depression and SSRIs. Selective serotonin reuptake inhibitors are widely prescribed in the UAE for anxiety and depression, especially in the expat workforce, and SSRI-induced sexual dysfunction is one of the most common reasons patients silently stop taking the medication. Reduced desire, delayed orgasm, and reduced arousal are all well-described class effects.
• Thyroid dysfunction. Subclinical hypothyroidism is under-diagnosed in the UAE adult population; low desire and fatigue are common presenting features. A TSH and free T4 take an afternoon to draw and interpret.
• Low testosterone. In men, biochemical hypogonadism is a structural cause of low desire and is treated by replacing the missing hormone, not by adding a peptide on top. In women, the picture is more nuanced and the evidence base for testosterone in female desire is narrower but real.
• Perimenopause. Women in their 40s in Dubai and Abu Dhabi increasingly raise this directly, and it deserves a structured workup, not reassurance. Estradiol decline, vaginal dryness with associated discomfort, and sleep disruption all feed into reduced desire.
• Sleep deprivation. Persistent under-sleeping suppresses sex hormones at the hypothalamic level. It is the single most common reversible contributor in working-age adults.
• Primary HSDD or FSIAD. After all the above are excluded, a subset of patients remain with persistent, distressing low desire that is not better explained by another factor. This is the population the on-label evidence for bremelanotide was generated in.

A clinic that prescribes a peptide before this differential has been worked through is not practicing medicine. It is dispensing.

The clinical workup before any prescription

Before bremelanotide or any sexual-health prescription is written, a competent UAE clinician runs a workup. The contents are unremarkable from an internist's perspective, which is the point: this is medicine, not specialty mystique.

• A directed history. Onset, duration, situational versus generalized pattern, current medications including any SSRI, beta-blocker, or oral contraceptive, mood, sleep, and a brief relational history. The history alone resolves a meaningful share of cases.
• Bloodwork. Thyroid function (TSH, free T4), fasting glucose and HbA1c, lipid panel, total and free testosterone with SHBG, prolactin, and FSH/LH where perimenopause is on the table. In men, an early-morning total testosterone is the appropriate first draw [Clayton et al., Mayo Clinic Proceedings, 2018].
• A medication review. SSRIs and SNRIs are the most common iatrogenic cause of reduced desire. Beta-blockers, certain oral contraceptives, opioids, and several antiepileptics are also implicated. Identifying the offending drug is sometimes the entire treatment.
• A blood pressure baseline. This matters specifically because bremelanotide transiently raises blood pressure and is contraindicated in uncontrolled hypertension, so a clinic that doesn't measure it before prescribing is missing a basic safety check.
• Cardiovascular risk screening. Cardiovascular disease is a contraindication, and the UAE adult population has higher background prevalence of metabolic and cardiovascular risk factors than the original trial cohorts. A reasonable threshold for a baseline ECG and lipid review is sensible.

What bremelanotide actually is

Bremelanotide is a synthetic peptide, seven amino acids long, that acts as an agonist at melanocortin receptors in the central nervous system, primarily MC4R. Its mechanism is upstream and neurological. It modulates the brain pathways that govern sexual interest. This is a fundamentally different mechanism from the better-known sildenafil family, which works peripherally by relaxing vascular smooth muscle so blood flow to genital tissue can be sustained.

The clinical implication is that bremelanotide is a desire drug, not an arousal-or-erection drug. It is the wrong tool for a patient whose problem is mechanical and the right tool for a patient whose problem is the absence of interest in the first place. Conflating the two leads to disappointment in both directions.

Originally developed as an analog of an endogenous melanocortin peptide, bremelanotide was studied in both men and women through the 2000s before the female HSDD program produced the registration trials [Diamond et al., Journal of Sexual Medicine, 2006].

The on-label evidence

The pivotal evidence comes from the RECONNECT program, two phase III trials in premenopausal women with acquired, generalized HSDD. The trials randomized participants to subcutaneous bremelanotide 1.75 mg as needed or placebo, used over 24 weeks, with co-primary endpoints of change in desire score and change in distress score [Kingsberg et al., Obstetrics & Gynecology, 2019].

Bremelanotide produced a statistically significant improvement on both endpoints versus placebo. The effect size was modest, with the responder analysis suggesting that roughly a quarter of treated patients achieved a meaningful improvement in desire and distress beyond what placebo achieved on its own. That is a real signal and it is also a clear-eyed picture: this is a drug that helps a measurable subset of patients, not a drug that transforms the response in everyone who takes it.

The honest framing for a patient considering it is that there's a roughly one-in-four chance of meaningful benefit on the trial endpoints, that the benefit is incremental rather than dramatic, and that the trade-off is a side effect profile most patients will notice. That is the same kind of risk-benefit conversation a patient deserves before any prescription.

How it compares to flibanserin

The other FDA-approved option for HSDD is flibanserin (Addyi), an oral medication taken daily that acts on serotonin 5-HT1A and 5-HT2A receptors. Flibanserin's effect size in trials was smaller than bremelanotide's, its onset is gradual rather than as-needed, and its side effect profile (sedation, hypotension, alcohol interaction) is generally considered less favourable [Clayton et al., Mayo Clinic Proceedings, 2018]. Neither drug is a step-change. They are tools, with different shapes, for the same general indication.

Off-label use in men

Bremelanotide's earliest clinical work was in men, exploring its potential in erectile dysfunction. The men's-health program did not lead to an on-label indication, partly because oral PDE5 inhibitors had already become the standard of care for the most common form of ED [Diamond et al., Journal of Sexual Medicine, 2006]. The on-label indication today is women only.

Some clinicians prescribe it off-label in men for whom desire, rather than mechanical arousal, is the limiting factor, particularly when sildenafil and tadalafil have been ineffective for that reason. Off-label is a clinical judgement call. It belongs to a doctor who has done the differential, ruled out hypogonadism, reviewed the medication list, and discussed the unlicensed nature of the indication with the patient.

Side effects, plainly

The bremelanotide side effect profile is well-characterized from the registration trials and post-marketing data [Simon et al., Journal of Women's Health, 2019]. It is not a quiet drug.

• Nausea. The most common side effect, reported by around 40% of trial participants, typically transient and most pronounced after the first one or two doses. Some patients pre-medicate with an antiemetic for the first few uses.
• Transient blood pressure elevation. Bremelanotide produces a small, time-limited increase in blood pressure following each dose, and a corresponding small reduction in heart rate. The effect is usually clinically inconsequential in healthy adults but is the reason the drug is contraindicated in uncontrolled hypertension and cardiovascular disease.
• Headache and flushing. Common, typically mild, typically transient.
• Injection site reactions. Mild irritation, redness, or tenderness at the injection site. Rotating sites and proper technique reduce incidence.
• Focal hyperpigmentation. A small subset of patients develop darkening of the gums, face, or breasts, more frequently with repeated dosing, because of the drug's family of melanocortin receptor activity. The labeling addresses it explicitly.

None of this is hidden in trial fine print. A patient deserves it laid out in plain language before the prescription is written.

How it's administered

Bremelanotide is delivered as a subcutaneous injection (typically into the abdomen or thigh) approximately 45 minutes before anticipated activity. It is dosed as needed, not daily, and the labeling caps use at one dose per 24 hours and no more than eight per month. The labeled dose is 1.75 mg [FDA prescribing information, Vyleesi].

The on-demand dosing is a meaningful clinical feature. It means the patient retains agency over when (and whether) to use it, which separates this drug from a daily-medication model and from the ongoing-commitment framing that surrounds many other prescriptions in this category.

Who should not take it

The contraindications are explicit and a clinician should walk through each one with the patient.

• Uncontrolled hypertension. The blood pressure effect is real; it is not safe in patients whose baseline pressure is uncontrolled.
• Established cardiovascular disease. Coronary disease, recent myocardial infarction, recent stroke, or significant arrhythmia.
• Pregnancy. The drug is contraindicated and patients of reproductive potential should be on reliable contraception.
• Active malignancy. As with most growth-pathway-active peptides, the conservative position is to avoid it.
• Age below 18. The trials did not enrol adolescents and there is no evidence base for use in this group.
• Patients on certain other medications. The clinic's medication review should specifically check for interactions; oral medications taken near the time of dosing may have absorption affected by the slowed gastric emptying associated with bremelanotide.

What a UAE pathway should look like

A responsible bremelanotide pathway in Dubai or Abu Dhabi has predictable steps, and the clinic that skips any of them is the clinic to walk away from.

• Consultation with a DHA- or DoH-licensed physician. This is a medical conversation, not a sales call. The physician's license number should be visible on the regulator's public registry.
• Differential and history. The clinical conversation works through relationship factors, mood and SSRI use, sleep, perimenopausal symptoms, and any other contributing factors before any prescription is on the table.
• Bloodwork. Thyroid, total and free testosterone with SHBG, prolactin, FSH/LH where indicated, fasting glucose and lipids. A baseline blood pressure, repeated, with at least one reading on a separate day if the first is borderline.
• Medication review. SSRIs in particular. If a current medication is the likely cause, addressing it (with the prescribing doctor) is the first step, not adding a second prescription.
• A written, dispensed prescription. Bremelanotide is dispensed by a licensed UAE pharmacy, with the auto-injector form properly labeled. Vials handed across a desk without dispensing infrastructure are diagnostic of a clinic operating outside the pharmacy framework.
• Patient education. How to inject, how to manage nausea, what to do if a dose produces a strong response either way, the dosing cap, and the contraindications. Plus a clear plan for what counts as a meaningful response and at what point the protocol stops if it isn't working.
• Follow-up. A check-in at 4 to 8 weeks. Sexual-health questionnaires (validated instruments, not vibes) at baseline and follow-up so improvement is documented rather than imagined.

The bottom line

Bremelanotide is a real, FDA-approved drug for a real, DSM-recognized clinical entity. The trial evidence is positive, the effect size is modest, and the side effect profile is meaningful but well-characterized. It is one of several tools, not a magic bullet, and it sits inside a workup-and-pathway framework that a competent clinic will follow without being prompted.

If low desire has become a source of personal distress, the right next step is a conversation with a licensed clinician, not a search of online vendors. The differential matters. The workup matters. So does the seriousness of the clinic you choose. This article is educational, not medical advice for your specific situation. Your medical history, current medications, and goals all matter, and a competent doctor will want all of them on the table before deciding whether bremelanotide, or anything else, is the right path for you.